Michael Raizman, MD
Enriched profileAssociate Professor of Ophthalmology, Tufts University School of Medicine · Ophthalmic Consultants of Boston
Michael Raizman is Associate Professor of Ophthalmology, Tufts University School of Medicine at Ophthalmic Consultants of Boston. ClinicalTrials.gov lists 4 registered studies with this person as an investigator.
Data verified 14 Aug 2026
Overview
Updated 31 Aug 2026
Michael B. Raizman, MD, is Associate Professor of Ophthalmology, Tufts University School of Medicine at Ophthalmic Consultants of Boston. The public record shows 135 publications with 4,058 citations (h-index 37), centered on Dry Eye / Uveitis. It also documents an investigator role on 4 registered clinical trials, industry payments reported by 18 companies, 2 NIH-funded awards (1986–1991).
- Top research focus: Dry Eye / Uveitis
- 4 registered trials on ClinicalTrials.gov
- Open Payments reporting from 18 companies
Generated from the cited public record · current as of 31 Aug 2026. Every fact links its source below.
Indications focus
from trials led + research topicsResearch focus
OpenAlex concept fingerprintDrugs & molecules
across trials, industry payments and publicationsWorks with
trial sponsors and companies reporting paymentsScholarship
indexed output and impact (OpenAlex)Hirsch index, productivity × impact (OpenAlex).
Clinical & industry
trials, payments and federal fundingContact
The practice address and phone this provider lists in the federal NPPES (CMS) registry.
Practice address
Telephone
Practice address and telephone from the federal NPPES registry.
Sign in to view contact details →Clinical trials
Updated 31 Aug 2026
Listed as an investigator on 4 registered studies on ClinicalTrials.gov. The most recent:
- Safety and Efficacy Study of Iontophoresis and Dexamethasone Phosphate to Treat Anterior Uveitis
Sponsor: Eyegate Pharmaceuticals, Inc.
- Study of Two Marketed Ocular Anti-Allergy Medications in Subjects With Allergic Conjunctivitis
Sponsor: Merck Sharp & Dohme LLC
Industry payments
Updated 31 Aug 2026
18 companies reported payments to CMS in program years 2021–2025. These are public disclosures, not judgments. The latest:
- Glaukos CorporationProgram year20253 payments
- Alcon Vision LLCProgram year20252 payments
- Rayner Intraocular Lenses LimitedProgram year20251 payment
Medicare prescribing footprint (2024)
The drugs this prescriber writes for Medicare patients, grouped by drug class and therapeutic area. Every percentage is a share of their total prescribing, so you can see what they prescribe most. These are proportions, not patient counts or dollar amounts. No condition is inferred: the claims record what was prescribed, never why.
Sensory organs
53.9%Corticosteroid28.2%Prednisolone Acetate94%Fluorometholone4%Pred Forte2%Part D<11 patientsCorticosteroids, plain11.3%Difluprednate80%Loteprednol Etabonate20%Part D≥169 patientsAnti-infectives
28.5%Fluoroquinolone Antibacterial23.3%Moxifloxacin100%Part D≥435 patientsHerpesvirus Nucleoside Analog DNA Polymerase Inhibitor2.2%Valacyclovir100%Part D≥25 patientsMusculoskeletal
12.4%Cyclooxygenase Inhibitor11%Ketorolac Tromethamine100%Part D≥207 patientsNonsteroidal Anti-inflammatory Drug1.4%Diclofenac Sodium100%Part D≥25 patients
Drug classes come from the WHO ATC and U.S. National Library of Medicine (RxClass) classifications; prescribing counts come from the CMS Medicare Part D Prescribers file. Each drug is counted once, under its primary class. Medicare fee-for-service only, so no Medicare Advantage, commercial, or pediatric prescribing is included. CMS publishes this data about 17 months after the fact.
NIH funding
Updated 31 Aug 2026
2 NIH research awards on record, funded 1986–1991 per NIH RePORTER. The latest:
Publications
Matched to this physician's OpenAlex author record; most-cited works shown first.
- Long-term Safety and Ocular Hypotensive Efficacy Evaluation of Netarsudil Ophthalmic Solution: Rho Kinase Elevated IOP Treatment Trial (ROCKET-2)
American Journal of Ophthalmology
2019 - Ophthalmic Drug Delivery Using Iontophoresis: Recent Clinical Applications
Journal of Ocular Pharmacology and Therapeutics
2019
Online presence
Updated 31 Aug 2026
This person's own public accounts first, then places where others mention them. Two different things, listed separately.
Owned accounts
public accounts run by this person- Doximity
doximity.com/pub/michael-raizman-md
verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →doximity.com ↗ - LinkedIn
linkedin.com/in/michael-raizman-203226212
provisionalFound in a cited public source but not yet independently corroborated. Published as a labeled candidate and queued for verification.How we verify →linkedin.com ↗ - ResearchGate
researchgate.net/scientific-contributions/Michael-B-Raizman-38891604
provisionalFound in a cited public source but not yet independently corroborated. Published as a labeled candidate and queued for verification.How we verify →researchgate.net ↗
Mentions by others
where others cite or feature them- Other
eventscribe.net/2022/Ophthalmology360/ajaxcalls/PresenterInfo.asp
verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →eventscribe.net ↗
We list an account only when the public record ties it to this person. verified means we've confirmed the match in more than one place; provisional means it looks right but we're still confirming.
Background & recognition
Updated 31 Aug 2026
Credentials, appointments and honors, newest first, each linked to the public source it came from.
Education
degrees and training on record- verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →doctors.massgeneralbrigham.org ↗
- verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →doctors.massgeneralbrigham.org ↗
- Residency
Ophthalmology, Kellogg Eye Center, University of Michigan
verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →eyeboston.com ↗ - Fellowship
Uveitis and Cornea, Massachusetts Eye and Ear Infirmary
verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →eyeboston.com ↗ - Fellow
American Academy of Ophthalmology
verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →eyeboston.com ↗
Editorial & leadership roles
journal and society appointments- Director
Corneal Fellowship Program and Cornea and Cataract Service, Tufts University School of Medicine
1992verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →streetinsider.com ↗ - Member
Cornea Society
verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →eyeboston.com ↗ - Member
American Society of Cataract and Refractive Surgery (ASCRS)
verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →eyeboston.com ↗
Awards & honors
honors on the public record- provisionalFound in a cited public source but not yet independently corroborated. Published as a labeled candidate and queued for verification.How we verify →eyeboston.com ↗
- provisionalFound in a cited public source but not yet independently corroborated. Published as a labeled candidate and queued for verification.How we verify →eyeboston.com ↗
- provisionalFound in a cited public source but not yet independently corroborated. Published as a labeled candidate and queued for verification.How we verify →eyeboston.com ↗
Secondary affiliations
appointments beyond the home institution- Chief Medical Officer
Palatin Technologies, Inc. (pharmaceutical company; oversees clinical/medical/regulatory affairs for its ocular pipeline including dry eye disease candidate PL9643)
verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →palatin.com ↗ - Physician
New England Eye Center at Tufts Medical Center
verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →neec.com ↗ - verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →eyeboston.com ↗
Media & interviews
press, podcasts and appearances- verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →palatin.com ↗
Every item links to where we found it. verified means we've confirmed it in more than one place; provisional means we found it and are still confirming.
Similar KOLs
Other experts from the same institution or the same specialty.